China, Swiss Pharmas Ink $534 Million Development, Marketing Deal
This article was originally published in PharmAsia News
Executive Summary
Fosun Pharma's drug-discovery unit, Fochon Pharma, and Sellas Clinicals Holding have signed an agreement with a potential value of $533.6 million for developing and marketing a pair of drugs, one for lung cancer, the other for diabetes.